The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | Non-genomic drivers of progression from MGUS to multiple myeloma
Felipe Prósper, MD, PhD, University of Navarra, Pamplona, Spain, shares insights into non-genomic drivers of progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma, drawing focus on the immune microenvironment and the bone marrow microenvironment. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, my talk was dealing really with some of the drivers that can induce transformation from MGUS to myeloma that are not genomic or epigenomic based. So mainly the main two non-genomic drivers are immune microenvironment. I didn’t talk about immune microenvironment. We had very nice talks from the group of Irene Ghobrial. And my talk was mainly focused on the bone marrow microenvironment, the non-immune microenvironment...
Well, my talk was dealing really with some of the drivers that can induce transformation from MGUS to myeloma that are not genomic or epigenomic based. So mainly the main two non-genomic drivers are immune microenvironment. I didn’t talk about immune microenvironment. We had very nice talks from the group of Irene Ghobrial. And my talk was mainly focused on the bone marrow microenvironment, the non-immune microenvironment. This is the mesenchymal stromal cells and endothelial cells. This is work that has some difficulties because these cells are very rare cells that are in the bone marrow. And being able to isolate those cells and interrogate them is part of the difficulties and why not many groups are working with those type of cells. So what we’ve found is that there are significant changes from the MGUS stage to the smoldering myeloma to the myeloma to the full symptomatic myeloma stage in those two populations. And some of those changes can actually be contributing to the development of the disease and even to the resistance to therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
